Business Relations Table - o4.fyi ()

Anmelden Gast|Guest
Beispiel: brt.php?search=wide&s=wide&p=adjective&o=wideness

Domain-Statistiken für "agentcapital.com"

118
Business Relations
116
Eindeutige Domains
20
Gefundene Einträge
BR-Relations: 118
From Domain Role To Domain Path Aktionen
/portfolio_website
/about-trex-bio/
/2017/12/aptinyx-raises-70-million-in-series-b-financing/
/2018/04/uk-gene-therapy-firm-orchard-plans-stock-offer-after-gsk-deal/
/2018/06/kauffman-fellows-celebrates-its-most-diverse-group-of-talented-leaders-with-class-23/
/2018/12/orchard-therapeutics-announces-the-build-out-of-new-gene-therapy-manufacturing-facility-in-california/
/2020/07/bristol-myers-pays-dragonfly-55m-to-bring-nk-cells-to-neuro-diseases/
/2023/01/agent-capitals-associate-jonathan-arks-phd-work-published-in-cell/
/2023/01/agent-capitals-associate-jonathan-arks-phd-work-published-in-cell/
/2023/03/passage-of-fda-modernization-act-2-0-opens-opportunities-for-new-alternative-methods-in-drug-development/
/2024/05/biosecure-act/
/2024/06/ashibio-raises-40m-in-seed-and-series-a-financing-to-advance-therapies-for-bone-and-connective-tissue-disorders/
/2024/06/ashibio-raises-40m-in-seed-and-series-a-financing-to-advance-therapies-for-bone-and-connective-tissue-disorders/
/2024/06/ashibio-raises-40m-in-seed-and-series-a-financing-to-advance-therapies-for-bone-and-connective-tissue-disorders/
/2024/06/ashibio-raises-40m-in-seed-and-series-a-financing-to-advance-therapies-for-bone-and-connective-tissue-disorders/
/2024/05/affini-t-therapeutics-announces-first-patient-dosed-in-kras-g12v-phase-1-program-and-presentation-of-trial-in-progress-poster-at-the-american-society-of-clinical-oncology-asco-2024-annual-meeting/
/2024/05/affini-t-therapeutics-announces-first-patient-dosed-in-kras-g12v-phase-1-program-and-presentation-of-trial-in-progress-poster-at-the-american-society-of-clinical-oncology-asco-2024-annual-meeting/
/2019/01/biogen-and-skyhawk-therapeutics-announce-agreement-to-develop-novel-small-molecule-rna-splicing-modifiers-for-neurological-disease-targets/
/2019/03/genome-editing-company-precision-proposes-100m-ipo/
/2019/05/carisma-therapeutics-featured-in-nature-biotechnologys-top-academic-spin-outs-2018/